ALNOV:EPA
Novacyt SA
€0.43
arrow_upward
+0.94%(+0.0040) 1D
Nov 5, 10:03:13 AM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNOV...
Open
€0.42
High
€0.43
Low
€0.42
Mkt. cap
31.02M
Avg. vol.
198.56K
Volume
5.47K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.38
Shares outstanding
72.59M
No. of employees
228
Open
€0.42
High
€0.43
Low
€0.42
Mkt. cap
31.02M
Avg. vol.
198.56K
Volume
5.47K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.38
Shares outstanding
72.59M
No. of employees
228
News stories
From web sources and news partners
www.tmgm.com
·
19 minutes ago
Dow Jones futures gains as traders eyeball US jobs data, corporate earnings
TradingView
·
2 hours ago
DJI: Dow Jones Jumps 3% in Stunning Post-Election Turnaround, AI Stocks Miss Out
Moomoo
·
2 hours ago
$Nasdaq Composite Index (.IXIC.US)$
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA
CEODavid Allmond
Employees228
FoundedJul 3, 2006
Headquarters-
SectorBiotechnology
Industry-
Websitenovacyt.com